Esters of (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl

Details Esters of (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl Esters of (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl

1999-06-22

2000-05-16

Seaman, D. Margaret

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

546239, C07D21134, A61K 31445

Patent

active

060637935

ABSTRACT:
The present invention is directed to esters of (+)-.alpha.-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidine methanol, pharmaceutical formulations, methods of making and methods of using these esters. These compounds antagonize the effects of serotonin at the 5HT.sub.2A receptor and are useful in treating various conditions such as, for example, psychoses such as schizophrenia.

REFERENCES:
patent: 2833775 (1958-05-01), Sperber et al.
patent: 3058979 (1962-10-01), Ullyot et al.
patent: 3194733 (1965-07-01), Yale et al.
patent: 3394131 (1968-07-01), Yale et al.
patent: 3655676 (1972-04-01), Kaiser et al.
patent: 4569941 (1986-02-01), Suh et al.
patent: 4623728 (1986-11-01), Sarges
patent: 4632929 (1986-12-01), Suh et al.
patent: 4701461 (1987-10-01), Suh et al.
patent: 4762842 (1988-08-01), Cohen et al.
patent: 4783471 (1988-11-01), Carr et al.
patent: 4804663 (1989-02-01), Kennis et al.
patent: 4810713 (1989-03-01), Yanni et al.
patent: 4877798 (1989-10-01), Sorensen et al.
patent: 4895841 (1990-01-01), Sugimoto et al.
patent: 4908369 (1990-03-01), Schechter et al.
patent: 4912117 (1990-03-01), Carr et al.
patent: 4921863 (1990-05-01), Sugimoto et al.
patent: 4950674 (1990-08-01), Yanni et al.
patent: 5021428 (1991-06-01), Carr et al.
patent: 5064838 (1991-11-01), Carr et al.
patent: 5070087 (1991-12-01), Teng et al.
patent: 5100901 (1992-03-01), Sugimoto et al.
patent: 5106855 (1992-04-01), McLees
patent: 5112978 (1992-05-01), Molinari
patent: 5116846 (1992-05-01), Caine et al.
patent: 5134149 (1992-07-01), Carr et al.
patent: 5158952 (1992-10-01), Janssen et al.
patent: 5169096 (1992-12-01), Carr et al.
patent: 5254556 (1993-10-01), Janssen et al.
patent: 5561144 (1996-10-01), Carr et al.
patent: 5618824 (1997-04-01), Schmidt et al.
patent: 5700812 (1997-12-01), Carr et al.
patent: 5700813 (1997-12-01), Carr et al.
patent: 5721249 (1998-02-01), Carr et al.
Pharmacology & Toxicology Supplement I, 1990, 5-7,E. Christensson, et al.
Pharmacology & Toxicology Supplement I, 1990, 12-17, B. Gustaffson, et al.
Life Sciences, vol. 47,pp. 2401-2408, J. Frank Nash, 1990.
Journal of Pharmacology and Experimental Therapeutics, vol. 253, No. 3, pp. 1162-1170, Saller, 1990.
Journal of Neurochemistry, vol. 54, No. 3 (1990),pp. 1062-1066, Nash, et al.
Jounal o Pharmacology and Experimental Theraputics, vol. 249, No. 3, pp. 673-679, Goldstein, et al, 1989.
Psychopharmacology (1989) vol. 99:S18-S27; H. Y. Meltzer.
Journal of Pharmacology and Experimental Therapeutics, vol. 251:238-246, Meltzer, 1989.
Internat'l Congress/Schizophrenic Research, Tucson, AZ--Presentation Abstract--Apr. 21-25 1991.
Internat'l Congress/Schizophrenic Research, Tucson, AZ--Presentation Abstract--Apr. 21-25.
Psychopharmacology (1989) vol.98:45-50; L. Ugedo, et al.
Drugs of the Future, vol. 14, No. 5 (1989), pp. 489-490.
Biochemical Pharmacology, vol. 36, No. 10 (1987), pp. 1715-1722; Nambu, et al.
Dencker, Svan Jonas, et al., Disease Management, CNS Drugs (1996), Nov:6(5)367-381.
Remington's Pharmaceuticals Sciences, "Sustained-release drug delivery systems," pp. 1687-1688 (1990), 18.sup.th edition.
Tetrahedron: Asymmetry, vol. 4, No. 5 (pp. 943-946) (1993), "Immobilization of substrate in enzyme catalyzed hydrolysis".
Tetrahedron: Asymmetry, vol. 1, No. 8 (pp. 535-536) (1990), "Enzymatic resolution of an arylpiperidine derivative utilizing lipase catalyzed hydrolysis".
Tetrahedron: Asymmetry, vol. 2, No. 2 (pp. 1'13-122) (1991), "Multigram lipase-catalyzed enantioselective acylation in the synthesis of the four stereoisomers of a new biologically active alpha aryl-4-piperidinemthanol derivative".
International Clinical Psychopharmacology (1997) vol. 12, pp. 255-261, R. Regenthal, et al.

Affiliated with

Also associated with

Rating

Esters of (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Esters of (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Esters of (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-259169